Connect with us

Science

She Lobbied for Formaldehyde. Now She’s at E.P.A. Approving New Chemicals.

Published

on

She Lobbied for Formaldehyde. Now She’s at E.P.A. Approving New Chemicals.

Formaldehyde, the chemical of choice for undertakers and embalmers, is also used in products like furniture and clothes. But it can also cause cancer and severe respiratory problems. So, in 2021, the Environmental Protection Agency began a new effort to regulate it.

The chemicals industry fought back with an intensity that astonished even seasoned agency officials. Its campaign was led by Lynn Dekleva, then a lobbyist at the American Chemistry Council, an industry group that spends millions of dollars on government lobbying.

Dr. Dekleva is now at the E.P.A. in a crucial job: She runs an office that has the authority to approve new chemicals for use. Earlier she spent 32 years at Dupont, the chemical maker, before joining the E.P.A. in the first Trump administration.

Her most recent employer, the chemicals lobbying group, has made reversing the Environmental Protection Agency’s course on formaldehyde a priority and is pushing to abolish a program under which the agency assess the risks of chemicals to human health. In recent weeks it has urged the agency to discard its work on formaldehyde entirely and start from scratch in assessing the risks.

The American Chemistry Council is also seeking to change the agency’s approval process for new chemicals and speed up E.P.A.’s safety reviews. That review process is a key part of Dr. Dekelva’s purview at the agency.

Advertisement

Another former chemistry council lobbyist, Nancy Beck, is back alongside Dr. Dekleva at the E.P.A. in a role regulating existing chemicals. The council’s president, Chris Jahn, told a Senate hearing shortly after the Trump inauguration that his group intended to tackle the “unnecessary regulation” of chemicals in the United States. “A healthy nation, a secure nation, an economically vibrant nation relies on chemistry,” he said.

It is not unusual or unlawful for industry groups to seek to influence public policy in the interest of their member companies. The A.C.C. estimates that products using formaldehyde support more than 1.5 million jobs in the United States.

What has been extraordinary, health and legal experts said, is the extent of the industry’s effort to block the E.P.A.’s scientific work on a chemical long acknowledged as a carcinogen, and how the architect of the effort was back at the agency as a regulator of chemicals. At the same time, the Trump administration has moved to sharply reduce the federal scientific work force.

“They already have a track record of ignoring the science,” said Tracey Woodruff, director of the Program on Reproductive Health and the Environment at the University of California, San Francisco. “Now, they’re in charge of government agencies that decide the rules.”

While leading the chemistry council’s fight to limit formaldehyde regulation, Dr. Dekleva called for investigations of federal officials for potential bias. The industry group used freedom of information laws to obtain emails of federal employees and criticized them in public statements for what they had written. It submitted dozens of industry-funded research papers to agencies that minimized the risks of formaldehyde.

Advertisement

The A.C.C. also sued both the E.P.A. and the National Academies, which advises the nation on scientific questions, accusing researchers of a lack of scientific integrity.

Allison Edwards, a chemistry council spokeswoman, said officials from the group had regularly met with E.P.A. staff members “to share critical science and to try and ensure an assessment of any chemistry is objective, employs rigorous scientific standards, and is reflective of real-world human exposure.” She said, “We’re asking to be one of many stakeholders at the table.”

Molly Vaseliou, a spokeswoman for the E.P.A., said the agency would continue to make sure it “ensures chemicals do not pose an unreasonable risk to human health or the environment.” At the same time, the agency would also work to approve “chemicals that are needed to power American innovation and competitiveness,” she said.

Formaldehyde’s fumes can cause wheezing and a burning sensation in the eyes, especially when they accumulate indoors. That danger was apparent when formaldehyde in plywood used to build temporary trailer homes for victims of Hurricane Katrina sickened dozens of people.

And there are longer-term dangers, namely several types of cancers. The World Health Organization’s International Agency for Research on Cancer concluded in 2004 that the chemical is a human carcinogen, and the U.S. Department of Health listed it as a human carcinogen in 2011.

Advertisement

The chemical is restricted in the workplace, in certain composite wood products, and in pesticides. Yet efforts to strengthen overall regulations in the United States have stalled in the face of industry opposition.

President Biden, whose “cancer moonshot” program had made reducing cancer deaths a priority, revived in 2021 an E.P.A. assessment of the health effects of the chemical, and published a draft the following year. That effort, under the agency’s Integrated Risk Information System, was the first step toward regulating formaldehyde.

The chemistry council led a coalition of industry groups, including the Composite Panel Association and Kitchen Cabinet Manufacturers, arguing that formaldehyde had already been rigorously studied and that strict industry controls were in place.

In a half-dozen letters to the E.P.A., Dr. Dekleva, on behalf of a formaldehyde panel at the industry group, raised a list of complaints about the way the agency was carrying out its assessment.

She questioned research linking formaldehyde to leukemia, or cancer of the blood, and accused the agency of not relying on the best available science. There was a dose, she said, at which formaldehyde did not cause risk. There was also research, she said, that showed inhaled formaldehyde did not easily travel beyond the nose to cause harm to the body.

Advertisement

In light of these issues, Dr. Dekleva wrote, agency’s draft assessment was “flawed and unreliable without significant revision.”

To bolster its case, the industry group enlisted experts at consulting firms to submit opinions and studies to the E.P.A. minimizing formaldehyde’s risks. The firms included those previously commissioned by tobacco companies to help defend cigarettes.

The A.C.C. also submitted 41 peer-reviewed studies that it said refuted a link between formaldehyde and leukemia. A New York Times review found that the majority of the studies were funded by industry groups, including at least 11 from the Research Foundation for Health and Environmental Effects, an organization established by the American Chemistry Council.

David Michaels, an epidemiologist and professor at George Washington University School of Public Health and assistant secretary of labor under President Barack Obama, said the industry strategy was to create the appearance of disagreement among scientists.

While it’s true, he said, that inconsistencies can always exist in studies on humans, “there’s little disagreement among independent scientists that formaldehyde causes cancer.”

Advertisement

For more than 150 years, the National Academies has advised the U.S. government on science. In 2021, it was asked to weigh in on the E.P.A.’s work on formaldehyde.

It became a target of the American Chemistry Council.

The industry group used freedom of information laws to obtain internal emails of members and support staff of a panel assessing the E.P.A.’s formaldehyde review, and it accused one staff of showing “bias in favor of disputed research claiming formaldehyde causes leukemia.”

The staff member, a former Environmental Protection Agency scientist, had for example described as “wonderful” the news that Congress might try to replicate an influential Chinese study that had shown formaldehyde could cause leukemia.

Wendy E. Wagner, professor at the University of Texas School of Law and an expert on the use of science by environmental policymakers, said she did not see how the comment reflected bias. “After all, they don’t know what the results will be, do they?” she said. “I would expect all scientists to be enthusiastic about potential future research.”

Advertisement

Dr. Dekleva called for investigations at both the E.P.A. and the National Academies, and for the removal of potentially biased panel members and staff. That included scientists who had previously accepted federal research grants.

In July 2023, the industry group sued the E.P.A., as well as the National Academies, accusing researchers of a lack of scientific integrity. The chemistry council said that lack of integrity made the use of the National Academies research in regulating formaldehyde “arbitrary, capricious, and unlawful.”

“It was relentless, and beyond the pale,” said Maria Doa, a scientist at the E.P.A. for 30 years who is now senior director of chemicals policy at the Environmental Defense Fund. “They really ratcheted up their attacks on federal employees.”

The National Academies stood its ground, issuing a report the following month affirming the E.P.A.’s Integrated Risk Information System findings that formaldehyde is carcinogenic and increases leukemia risk.

Those conclusions are shared by other global health authorities.

Advertisement

Mary Schubauer-Berigan, the evidence-synthesis head at the World Health Organization’s Agency for Research on Cancer, said there was “sufficient evidence in humans” that formaldehyde causes leukemia as and nasopharynx cancer. Mikko Vaananen, a spokesman for the European Chemicals Agency, said that while some questions around specific links to leukemia remained unanswered, evidence was sufficient to classify formaldehyde as a carcinogen. Formaldehyde “cannot in principle be placed on the E.U. market,” he said.

In March 2024, a federal judge dismissed the chemistry council’s lawsuit. And early this year, near the end of the Biden administration, the E.P.A. issued a final risk determination, under the Toxic Substances Control Act: Formaldehyde “presents an unreasonable risk of injury to human health.”

Mary A. Fox, an expert in chemical risk assessment at the Johns Hopkins University Bloomberg School of Public Health and a member of a committee that reviewed the E.P.A.’s research on formaldehyde, said agency scientists had accurately reflected the uncertainties around the links between formaldehyde and leukemia. But they had documented many other streams of evidence that indicated that link, Dr. Fox said.

“It’s an inevitable progress of science, that as we learn more over time, we generally learn that health effects appear at lower concentrations than we had thought,” she said.

Following Mr. Trump’s re-election, the American Chemistry Council signed onto a letter from a range of industry groups calling for broad changes to policy, specifically citing formaldehyde. “We urge your administration to pause and reconsider” the E.P.A. findings on formaldehyde, the Dec. 5 letter said.

Advertisement

The E.P.A. “should go back to the scientific drawing board,” chemistry council said in January. The group was particularly concerned about the workplace limits the agency was suggesting, which it said ignored steps companies were already taking to protect workers, like the use of personal protective equipment.

The A.C.C. is also supporting a bill from Republican members of Congress that would end the Integrated Risk Information System.

Soon after, Trump transition officials said Dr. Dekleva would be returning to the E.P.A. to run a program assessing chemicals for approval. The chemistry council, which has long complained of a backlog, is pushing the agency to speed up approvals.

During the first Trump administration, agency whistle-blowers described in an inspector general’s investigation how they had faced “intense” pressure to eliminate the backlog, sometimes at the expense of safety. Shortly after the inauguration, the Trump administration fired the inspector-general who carried out the investigation.

On Jan. 20, the A.C.C. welcomed President Trump. “Americans want a stronger, more affordable country,” said Mr. Jahn, the group’s president. “America’s chemical manufacturers can help.”

Advertisement

Science

Trump Plans to Fire F.D.A. Commissioner Marty Makary

Published

on

Trump Plans to Fire F.D.A. Commissioner Marty Makary

President Trump has signed off on a plan to fire Dr. Marty Makary, commissioner of the Food and Drug Administration, after a series of clashes over vaping, oversight of the abortion pill and a series of new drug application denials that rattled biotech companies, according to a person briefed on the matter, who was not authorized to discuss it publicly.

Dr. Makary had a high profile for an F.D.A. commissioner, appearing frequently on television and podcasts to sell the work he was doing at the agency on improving the food supply, speeding up some drug approvals and trying to restore agency morale after thousands of staff members left.

He tried to walk the tightrope between the business-friendly Make America Great Again movement, pledging to get rid of regulations that slow down innovation and to attract more drug trials to the United States. He was an ally of Health Secretary Robert F. Kennedy Jr.’s Make American Healthy Again supporters, voicing the skepticism of the pharmaceutical industry and authorizing natural food dyes.

Ultimately, Dr. Makary’s efforts were not enough to overcome the grievances of a growing band of enemies focused on selling tobacco, opposing abortion and seeing biotech therapies authorized.

Mr. Trump’s decision to dismiss him was first reported by The Wall Street Journal.

Advertisement

The decision could still change, given Mr. Trump’s propensity to change his mind Dr. Makary has also proven persuasive with Mr. Trump in beating back previous efforts to oust him.

Leaving the White House Friday evening, Mr. Trump dismissed the idea that Dr. Makary would be fired.

“I’ve been reading about it, but I know nothing about it,” he said.

The White House has pressured Dr. Makary for months to authorize flavored e-cigarettes, according to a person close to the conversations. The approvals were a top wish of major tobacco companies that have been top donors to Mr. Trump. In March, the F.D.A. issued a memo saying that it would only authorize e-cigarettes in flavors such as mint, tea and spices. The memo said the fruit and candy flavors would be unlikely to pass muster, given their appeal to young people.

Pressure continued, though, and on Tuesday the F.D.A. authorized blueberry and mango flavored e-cigarettes by Glas, a small company based in Los Angeles.

Advertisement

Abortion foes including Susan B. Anthony Pro-Life America have continued to turn up the heat on Dr. Makary, reiterating their call for his firing on Thursday. The group’s leaders and others view Dr. Makary as dragging his feet on a safety review of the abortion pill mifepristone, which they viewed as a way to highlight what they believe are dangers of the drug. Former Vice President Mike Pence, who also opposes abortion rights, amplified criticism of Dr. Makary on social media as well.

The administration has been under pressure from conservatives to tighten regulations on the prescribing and dispensing of mifepristone. The Supreme Court is reviewing a federal appeals court ruling that temporarily blocked abortion providers from prescribing the drug through telemedicine and sending it to patients by mail.

Biotech companies and their investors have also raised alarms with the White House about agency decisions to reject a series of treatments for rare diseases. The F.D.A. typically turns down about 20 percent of the applications it receives for drug approvals from companies.

Dr. Makary has been aggressive in defending the decisions, which he said came from career scientists who found the medications ineffective.

Dr. Makary also had to contend with a health secretary who seemed to view the F.D.A. as an avenue for getting his favored products authorized, exemplified by Mr. Kennedy’s social media post saying that the agency would end its “war on” stem cell treatments, peptides and raw milk. Mr. Kennedy pushed the F.D.A. to reverse a 2023 ban and allow the use of a number of peptides, unproven compounds purported to offer anti-aging or muscle-recovery benefits.

Advertisement

Before leading the F.D.A., Dr. Makary was a cancer surgeon and health policy researcher at Johns Hopkins University School of Medicine. He was also the author of several books about the health care system.

Some of Dr. Makary’s more popular moves included encouraging broader use of hormone replacement products for women and lifting the F.D.A.’s warnings on them. He helped speed some promising drugs to market, including a pancreatic cancer therapy and the pill form of the popular GLP-1 weight loss drugs.

Continue Reading

Science

Californians were aboard hantavirus-stricken cruise ship. Is there a risk to the public?

Published

on

Californians were aboard hantavirus-stricken cruise ship. Is there a risk to the public?

Some California residents were among the 147 passengers and staff aboard a luxury cruise ship stricken by a suspected outbreak of hantavirus that has left three people dead and several others severely ill, officials confirmed Thursday.

California public health officials say they are monitoring the situation after being notified by the U.S. Centers for Disease Control and Prevention that some state residents were passengers on the MV Hondius. The precise status of those individuals, however, remains murky.

Hantavirus is a rare but deadly disease that attacks the lungs and is typically contracted by humans through inhalation of particles contaminated with the urine, feces or saliva of a wild rodent.

However, Dr. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, confirmed Thursday that the Andes virus — a form of hantavirus that can spread from person to person — was involved in the outbreak.

Here’s what we know:

Advertisement

The MV Hondius cruise ship anchored at a port in Praia, Cape Verde, on Wednesday.

(Misper Apawu / Associated Press)

As its name suggests, the Andes virus is typically found in South America. The Dutch-flagged MV Hondius was on a 46-day journey that traveled from Antarctica with stops in Argentina.

In the case of human-to-human transmission, a person would first be infected by a wild rodent’s contaminated particles and then pass the infection to someone else, said Dr. Gaby Frank, director of the Johns Hopkins Special Pathogens Center.

Advertisement

“In previous outbreaks of Andes virus, transmission between people has been associated with close and prolonged contact, particularly among household members, intimate partners and people providing medical care,” Ghebreyesus said. “That appears to be the case in the current situation.”

None of the remaining passengers or crew members on the ship are symptomatic, he said.

The ship was not permitted to allow passengers to disembark at its original destination, Cape Verde, and is sailing for Spain’s Canary Islands.

“I want to be unequivocal here: This is not SARS-CoV-2. This is not the start of a COVID pandemic. This is an outbreak that we see on a ship. There’s a confined area,” Dr. Maria Van Kerkhove, who leads the WHO’s epidemic and pandemic management, said at a briefing. “This is not the same situation we were in six years ago. It doesn’t spread the same way like coronaviruses do.”

California passengers on the cruise

On April 1, 114 guests boarded the cruise ship in Ushuaia, Argentina. Twenty-three days later, 30 passengers — including six people from the United States — disembarked on a stop in St. Helena, a remote island about 1,100 miles off the coast of Africa, according to the cruise operator Oceanwide Expeditions.

Advertisement

Public health agencies in California, Georgia and Arizona were notified by the CDC that some of their residents were among the passengers on the cruise. It’s unclear whether these individuals disembarked on April 24, however.

The CDC is assisting local health authorities with monitoring California residents who were aboard the cruise, according to a statement by the California Department of Public Health on Friday.

As of Friday, one passenger has returned to their California residence and is in contact with local public health officials, and at least one other remains aboard the ship, according to the state agency.

“We understand that news of an unusual outbreak can be concerning,” said Dr. Erica Pan, director of the California Department of Public Health. “Unlike influenza and COVID-19, years of experience in South America have shown that this Andes hantavirus rarely spreads between people.”

Officials said the current public health protocol is to do daily symptom monitoring and reporting.

Advertisement

“As there are no known cases of Andes hantavirus infection from people without symptoms, and any spread has usually been limited to people with prolonged close contact with an ill person with this virus, the risk to the general public in California is extremely low,” the agency said in a statement.

In a statement earlier this week, the CDC also said that the risk to the American public “is extremely low” at this time.

“We urge all Americans aboard the ship to follow the guidance of health officials as we work to bring you home safely,” the agency said.

The others who exited the ship on April 24 were individuals from Canada, Denmark, Germany, the Netherlands, New Zealand, Switzerland, Sweden, Singapore, St. Kitts and Nevis, Turkey and the United Kingdom.

Of the remaining passengers still aboard the ship headed for Spain’s Canary Islands, California Department of Public Health said none were ill as of Friday.

Advertisement

How many people have been infected?

The number of lab-confirmed hantavirus cases has risen to five, according to the WHO. There are three additional suspected cases.

A timeline of reported cases of hantavirus aboard the cruise ship can be found here.

The WHO is monitoring reports of other people with symptoms “who may have had contact with one of the passengers. In each case, we are in close contact with the relevant authorities,” Tedros said.

The first passenger to have been infected, a Dutchman, became sick aboard the cruise ship on April 6 and died on April 11.

No samples were taken, because his symptoms were similar to other respiratory diseases. His widow left the ship with his body on April 24 during the scheduled stop at St. Helena.

Advertisement

“She deteriorated during a flight to Johannesburg on the 25th of April and died the next day,” Tedros said.

Before boarding the cruise ship, the Dutch couple had traveled through Argentina, Chile and Uruguay on a bird-watching trip, “which included visits to sites where the species of rat that is known to carry Andes virus was present,” Tedros said.

After leaving the ship, the woman was briefly aboard a KLM aircraft in Johannesburg bound for Amsterdam but was barred from the flight due to her medical condition, the airline said in a statement.

Dutch news outlets reported that a flight attendant on a KLM airplane — who briefly had contact with the widow — started feeling sick and had mild symptoms and was in isolation at a hospital in Amsterdam.

The flight attendant has since tested negative for the Andes virus, Dr. Jeremy Faust, an emergency medicine physician, wrote on his Substack blog, Inside Medicine, citing a text message sent to him by Tedros.

Advertisement

“It is still possible that the flight attendant contracted the Andes virus. However, given our understanding of the virus, this information means that the flight attendant’s symptoms are not caused by the Andes hantavirus, but by some other medical illness,” Faust wrote.

More cases may be reported, because the incubation period — the time it takes between exposure to the virus and the onset of illness — for the Andes strain of the hantavirus is up to six weeks.

What we know about hantavirus

There are roughly 50 identified species of hantavirus. The virus that’s found in the Americas tends to cause a cardiopulmonary syndrome, a condition that affects the heart and the lungs, according to Frank.

There have been 890 laboratory-confirmed cases of hantavirus disease reported in the U.S. since surveillance began in 1993, according to the most recent data from the CDC.

From 1980 to 2025, 99 California residents have been diagnosed with a hantavirus infection, according to the California Department of Public Health.

Advertisement

CDC officials said 38% of people who develop respiratory symptoms may die from the disease.

Still, the data suggest that contracting hantavirus is rare, said Dr. Afif El-Hasan, member of the American Lung Assn.’s national board of directors.

There is no vaccine or specific antiviral medicine for hantavirius.

Intensive-care treatment may include intubation and oxygen therapy, fluid replacement and use of medications to lower blood pressure, according to the American Lung Assn.

The signs of hantavirus

Early symptoms of hantavirus are similar to the flu and include fatigue, fever and muscle aches, according to the CDC. Symptoms start to develop within one to eight weeks after contact with an infected rodent.

Advertisement

Half of those who contract the virus also experience headaches, dizziness, chills, nausea, vomiting, diarrhea and abdominal pain.

Four to 10 days after the initial phase of the illness, another round of symptoms can develop, which include coughing, shortness of breath and possible tightness in the chest as the lungs fill with fluid.

Even though contracting hantavirus in the U.S. continues to be a rare event, El-Hasan said, people should take these initial symptoms seriously and promptly seek medical care.

How to protect yourself

Hantavirus cases can occur year-round, but the peak seasons in the United States are the spring and summer, which coincide with the reproductive seasons for deer mice.

To lessen your risk of infection, keep wild rodents out of your home and other enclosed spaces by sealing any holes and placing snap traps.

Advertisement

If you find evidence of mice, wear personal protective equipment and disinfect the area. When you’re done, put everything, including cleaning materials, in a bag and toss it in your trash bin.

Continue Reading

Science

Hantavirus Is Nothing Like Coronavirus, but It’s Bringing Some ‘Covid P.T.S.D.’

Published

on

Hantavirus Is Nothing Like Coronavirus, but It’s Bringing Some ‘Covid P.T.S.D.’

Medical workers in protective suits. Contact tracing. P.C.R. tests and World Health Organization briefings.

Just when much of the public had presumed to have left those ominous images and turns of phrase intertwined with the Covid-19 pandemic in the rearview mirror, a deadly hantavirus outbreak aboard a Dutch cruise ship has dredged up familiar anxieties.

Health experts, aware of the scars Covid left on people, including those who are still dealing with it, have sought to dispel comparisons between hantavirus and coronavirus. They said this week that the viruses spread quite differently and were not close in magnitude.

Still, those reassurances have not quelled the public’s anxiety or its appetite for medical advice from some of the same doctors who commanded attention on television as Covid-19 marched across the globe.

“I have Covid P.T.S.D.,” Dr. Celine R. Gounder, editor at large for public health at KFF Health News and an infectious disease expert, said in an interview on Thursday. “There are parts of New York City I cannot walk by without seeing the refrigerated mortuary trucks. I had to get rid of certain things I was using during the pandemic, clothing or otherwise, because it was triggering. So I completely get where people are coming from.”

Advertisement

“That said,” Dr. Gounder was swift to emphasize, “not all infectious diseases are created equal.”

In Spain, the president of the Canary Islands lodged a protest against allowing the cruise ship to dock there, while a flurry of threads have begun to appear on social media sites pondering whether it was safe to travel at all.

The mention of masks particularly reverberated on the far right politically, where some have begun using the outbreak to warn against the prospect of new restrictions or government mandates.

Three passengers who were traveling on the Dutch cruise ship MV Hondius died during the hantavirus outbreak, which has sickened at least five other people aboard the vessel with symptoms of the rare disease. On Sunday, the ship is expected to approach the island of Tenerife, where passengers will be brought by boats for evacuation flights to their home countries.

Most strains of the virus, which is primarily carried by rodents, cannot be spread from person to person. But the one identified in the ship outbreak, the Andes strain, can move between people, according to medical experts, who underscored that it requires repeated close contact.

Advertisement

“This is not coronavirus,” Dr. Maria Van Kerkhove, the W.H.O.’s head of epidemic and pandemic preparedness, said at a news conference in Geneva on Thursday. “This is a very different virus.”

Dr. Van Kerkhove said she could understand the intense demand for answers about the cluster of infections.

“I want to be unequivocal here: This is not SARS-CoV-2,” she said, referring to the virus that causes Covid. “This is not the start of a Covid pandemic.”

Around the world, health authorities monitored suspected cases of hantavirus infection. A number of these potential patients tested negative. But the concerns were a reminder of how every allergy season sneeze or wheeze could prompt existential dread in the early months of the Covid pandemic.

In an appearance on the “Today” show on Thursday, Dr. Ashish Jha, who oversaw the Biden administration’s pandemic response as it wound down, said he was confident that public health authorities could contain the spread of the hantavirus if they followed longstanding contact tracing protocols.

Advertisement

“We’ve got to track down everybody who left the cruise ship and figure out where they are, make sure that we’re monitoring them,” he said. “If they develop any symptoms, then they’ve got to get isolated.”

Such attempts at reassurance may be interpreted differently by some critics of the Trump and Biden administration’s responses to the Covid pandemic.

The far-right commentator Glenn Beck on Thursday signaled the need to resist a return to Covid-era measures on his show.

“They’ll do exactly the same thing they did last time, and then our kids won’t go to school, and we’ll have masks,” Mr. Beck said.

Plenty of others on social media sought to introduce levity in the moment, harking back to quirky rituals and skills they honed during the pandemic.

Advertisement

“Practicing my dancing for when the hantavirus becomes the new covid,” one young woman wrote in a post.

Continue Reading
Advertisement

Trending